By 2022, the trajectory had become unambiguous enough that the board authorized Udvarhelyi to find a partner
The current evidence suggests that: Dose-dependent efficacy : Both glycaemic and weight outcomes improve with increasing doses within the therapeutic range, suggesting that very low doses are unlikely to provide substantial benefit
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
The machine was originally designed to sculpt the jawline, but doctors have been using it off-label as FDA approvals trickle in
When food reaches your intestine, it triggers the release of hormones that signal to other parts of your body
healthcare billing, maintained jointly by CMS and the CDCs National Center for Health Statistics (CDC NCHS, ICD-10-CM)
